OncoMatch/Clinical Trials/NCT07166419
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Is NCT07166419 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Autologous Anti-CD19/CD20/CD22 CAR T-cells and Cyclophosphamide for blast phase chronic myeloid leukemia, bcr-abl1 positive.
Treatment: Autologous Anti-CD19/CD20/CD22 CAR T-cells · Cyclophosphamide · Fludarabine — This phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as CD19, CD20 and CD22, on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving TriCAR19.20.22 T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory non-Hodgkin lymphoma, ALL and CLL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease
Required: CD20 overexpression
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease
Required: CD22 overexpression
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton's tyrosine kinase inhibitor — chronic lymphocytic leukemia
must have previously received an approved Bruton's tyrosine kinase (BTK) inhibitor
Must have received: BCL2 inhibitor (venetoclax) — chronic lymphocytic leukemia
must have previously received ... venetoclax
Must have received: tyrosine kinase inhibitor — chronic myeloid leukemia, lymphoid blast crisis
received at least 2 prior lines of therapy (tyrosine kinase inhibitors, multiagent chemotherapy)
Must have received: multiagent chemotherapy — chronic myeloid leukemia, lymphoid blast crisis
received at least 2 prior lines of therapy (tyrosine kinase inhibitors, multiagent chemotherapy)
Cannot have received: autologous stem cell transplant
Exception: relapse within 12 months of autologous stem cell transplant for refractory high-grade B-cell lymphoma
Autologous transplant within 6 weeks of planned CAR-T cell infusion
Cannot have received: allogeneic stem cell transplant
Allogeneic stem cell transplant or donor lymphocyte infusion within 2 months of planned CAR-T cell infusion and patients must be off immunosuppressive agents
Lab requirements
Blood counts
Absolute lymphocyte count ≥ 100/uL; if WBC is low and differential is not performed, CD3 count (helper/suppressor) should be ≥ 100/ul
Kidney function
Creatinine clearance ≥ 50 ml/min calculated by the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 times the institutional upper limit of normal; AST (SGOT) ≤ 3 x institutional upper limit of normal; ALT (SGPT) ≤ 3 x institutional upper limit of normal
Cardiac function
Left ventricular ejection fraction ≥ 40% in the most recent echocardiogram
Total bilirubin ≤ 1.5 times the institutional upper limit of normal; AST (SGOT) ≤ 3 x institutional upper limit of normal; ALT (SGPT) ≤ 3 x institutional upper limit of normal; Creatinine clearance ≥ 50 ml/min calculated by the Cockcroft-Gault formula; Absolute lymphocyte count ≥ 100/uL; if WBC is low and differential is not performed, CD3 count (helper/suppressor) should be ≥ 100/ul; Left ventricular ejection fraction ≥ 40% in the most recent echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify